Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
NCT ID: NCT05224960
Last Updated: 2024-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
140 participants
INTERVENTIONAL
2024-06-27
2027-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
NCT05121870
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1b)
NCT05984303
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
NCT05227846
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
NCT03529136
Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
NCT01220492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mesenchymal stem cells (MSC) are a kind of pluripotent stem cells belonging to mesoderm, which mainly exist in connective tissue and organ interstitium. At present, MSC can be isolated and prepared from bone marrow, fat, synovium, bone, muscle, lung, liver, pancreas and amniotic fluid and umbilical cord blood . Due to its wide range of sources and self-proliferation and differentiation ability, MSCs have therapeutic potential for many diseases, including acute and chronic liver diseases.
In recent years, our team has carried out a series of clinical trials using umbilical cord-derived MSCs to treat patients with end-stage liver disease, decompensated cirrhosis, primary biliary cholangitis, and status after liver transplantation and found that MSCs therapy can significantly improve patient liver function, reduce post-transplantation rejection, reduce complications, improve quality of life, and improve survival. Other investigators have also found in clinical trials with MSCs from different sources that treatment with MSCs can improve MELD scores or liver function levels to varying degrees. However, some studies have found no significant difference between the treatment group and the control group, and MSCs may differentiate into hepatic stellate cells and have the risk of promoting liver fibrosis, it is believed that MSCs do not favor the improvement of liver function in these studies. Therefore, the therapeutic effects of MSCs need to be further validated by larger multicenter randomized controlled clinical trials.
The investigators will do a prospective, double-blind, muliticenter, randomised trial to assess treatment with three intravenous doses of MSCs compared with placebo. 140 decompensated cirrhosis patients will be recruited in China. 70 patients will receive i.v. transfusion 3 times of MSCs and the standard of care as the treated group. In addition, the 70 patients will receive placebo and standard of care as control group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)
UC-MSCs plus standard of care (SOC).
UC-MSCs
3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
Placebo
Placebo plus SOC.
Placebo(solution without UC-MSCs)
3 doses of placebo intravenously at day 1, day 8, day 15.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UC-MSCs
3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
Placebo(solution without UC-MSCs)
3 doses of placebo intravenously at day 1, day 8, day 15.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged 18 to 75 years (including 18 and 75 years), male or female;
3. Patients diagnosed with decompensated liver cirrhosis based on clinical findings, laboratory tests, imaging findings and/or representative pathological findings (decompensated liver cirrhosis is defined as the occurrence of at least one serious complication, including esophageal and gastric varices bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis and other serious complications);
4. The Model for End-stage Liver Disease (MELD) score 15 to 30 points.
Exclusion Criteria
2. Uncontrolled severe infection within 2 weeks of screening.
3. Patients with hepatitis B virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HBV for less than 12 months, or hepatitis B virus (HBV) DNA ≥ detection limit at the time of screening.
4. Patients with hepatitis C virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HCV for less than 12 months, or hepatitis C virus (HCV) RNA ≥ detection limit at the time of screening (except HCV RNA\< detection limit without any antiviral treatment).
5. Patients under treatment with corticosteroids for autoimmune hepatitis for less than 6 months.
6. Trans-jugular intrahepatic portosystemic shunts (TIPS) insertion within 6 months prior to study inclusion.
7. Active drinkers with alcohol-related decompensated cirrhosis are unwilling to stop alcohol abuse after inclusion.
8. Significant renal insufficiency (serum creatinine ≥ 1.2 times upper normal limit); Severe electrolyte abnormality (serum sodium level \< 125 mmol/L); Severe leukopenia (white blood cell count \< 1 × 10E9/L).
9. Patients with biliary obstruction, or portal vein spongiosis.
10. Patients with surgical history such as splenic cut-off flow.
11. Patients with malignant tumors within 5 years, except those with basal cell carcinoma, squamous cell carcinoma and/or carcinoma in situ who had received curative treatment and curative resection.
12. Patients with a prior history of major organ transplantation or complicated with significant disease of heart, lung, kidney, blood, endocrine and other systems.
13. Drug abuse, drug dependence and patients who receive methadone treatment or with psychosis.
14. Against the human immunodeficiency virus antibody (Anti - HIV) or syphilis antibody test results were positive.
15. Pregnancy, lactation or with recent fertility plan during the test and 6 months after the test.
16. Highly allergic, or have a history of severe allergies, known severe allergies to the investigational drug or any of the excipients.
17. History of pulmonary embolism.
18. Patients who had previously received stem cell therapy or were intolerant to cell therapy.
19. The proposed line of liver transplants within three months.
20. Participants in other clinical trials within the last 3 months.
21. Any other clinical condition which the investigator considers would make the patient unsuitable for the trial.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
LanZhou University
OTHER
Jin Yin-tan Hospital
UNKNOWN
Hainan Hospital of Chinese PLA General Hospital
UNKNOWN
Vcanbio Cell and Gene Engineering Corp., Ltd.
INDUSTRY
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Xinjiang Kashi Area Number 1 Hospital
UNKNOWN
Beijing 302 Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fu-Sheng Wang
Head of Treatment and Research Center for Infectious Diseases, Principle Investigator, Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fu-Sheng Wang, MD, PhD
Role: STUDY_CHAIR
Beijing 302 Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Hainan hospital of Chinese PLA General Hospital
Sanya, Hainan, China
Jin Yin-tan Hospital
Wuhan, Hubei, China
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Xinjiang Kashi Area Number 1 Hospital
Kashgar, Xinjiang, China
Beijing 302 Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSC-DLC-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.